Fox Chase Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fox Chase Cancer Center sits in the top decile of US sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count).
Fox Chase Cancer Center: 183 sponsored US clinical trials, 29 recruiting.
Fox Chase Cancer Center sponsors 183 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 104 completed. 5 of these trials are in Phase 3-4 (later-stage) and 107 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urothelial Carcinoma, with 6 trials.
Top-decile sponsor footprint
Fox Chase Cancer Center ranks in the top decile of sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
104 of 137 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
183 total, page 4 of 4
Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer
NCT00084539
Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer
NCT00084526
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
NCT00066677
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
NCT00244868
Computed Tomography in Detecting Movement of the Esophagus in Patients Undergoing Radiation Therapy to the Chest
NCT00433524
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00062296
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00062322
Smoking Cessation for Low-Income Pregnant Women
NCT02211430
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00043108
A New Radiation Therapy Planning System in Patients Undergoing Radiation Therapy for Cancer
NCT00436397
Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer
NCT00039507
Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer
NCT00062309
Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
NCT00039520
Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer
NCT00022711
Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
NCT00322296
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
NCT00006013
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
NCT00021320
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005848
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
NCT00005037
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
NCT00021333
Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
NCT00021359
Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00022308
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00003957
Facilitating Participation in a Prostate Cancer Risk Assessment Program
NCT02126319
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
NCT00003943
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00003944
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
NCT00003109
Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors
NCT00021346
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
NCT00003264
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
NCT00003263
Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer
NCT00021398
Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
NCT00005021
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00021372
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 45 |
| Phase 2 | 62 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Fox Chase Cancer Center pipeline
29 recruiting of 183 indexed (16% open); 104 completed (57%).
Phase mix: 5 late (III/IV) vs 107 early (I/II) (early-phase heavy).
Top condition: Urothelial Carcinoma (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fox Chase Cancer Center: open-pipeline peers nationwide
Peers matched on 183 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Fox Chase Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 183 trials (± recruiting share)
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- ViiV Healthcare · 182 trials · 4% recruiting
- Boston University · 185 trials · 12% recruiting
- National Human Genome Research Institute (NHGRI) · 185 trials · 16% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- University of California, San Francisco · 16% recruiting · 1,713 trials
- Youngstown State University · 16% recruiting · 19 trials
- University of Southern California · 16% recruiting · 617 trials
Related
What to do with this Fox Chase Cancer Center page
183 registered trials is a research-attention snapshot, not an endorsement of Fox Chase Cancer Center or any single study.
- 29 of Fox Chase Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urothelial Carcinoma is the condition Fox Chase Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urothelial Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fox Chase Cancer Center pipeline card: 183 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.